Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | ALPL | P05186 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18912106 | 0.79 | NPC1 (0.40) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL643747 | 0.79 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL18912105 | 0.77 | NPC1 (0.44) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5495466 | 0.74 | CYP3A4 (0.49) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL16169 | 0.73 | PI4KA (0.59) | RAB9ASMN1; SMN2ALDH1A1TP53LMNA | |
| SCHEMBL1970070 | 0.73 | GDA (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL5196527 | 0.72 | SPHK2 (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL2429096 | 0.71 | METAP2 (0.49) | SMN1; SMN2MAPTLMNAGAAMEN1 | |
| SCHEMBL10644622 | 0.70 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL10774219 | 0.69 | ENPP1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1108724-B1 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | SIRNA THERAPEUTICS INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-6972330-B2 | Contacting N4-acetyl-5',3'-di-O-acetyl-2'-O- methyl cytidine with Lewis acid to form 2'-)-methyladenosine nucleoside which is converted to phosphoramidite | SIRNA THERAPEUTICS, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | RIBOZYME PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204078-A1 | Chemical synthesis of methoxy nucleosides | UMPS, PNP, NUDT1 | RAB9A 3754/4885NPC1 1394/4885SMN1; SMN2 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.